279 related articles for article (PubMed ID: 32125749)
1. Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using
Lee JS; Kim SY; Chun YS; Chun YJ; Shin SY; Choi CH; Choi HK
Neurogastroenterol Motil; 2020 Jun; 32(6):e13830. PubMed ID: 32125749
[TBL] [Abstract][Full Text] [Related]
2. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome.
Zhang WX; Zhang Y; Qin G; Li KM; Wei W; Li SY; Yao SK
World J Gastroenterol; 2019 Nov; 25(43):6416-6429. PubMed ID: 31798278
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics analysis revealed metabolic changes in patients with diarrhea-predominant irritable bowel syndrome and metabolic responses to a synbiotic yogurt intervention.
Noorbakhsh H; Yavarmanesh M; Mortazavi SA; Adibi P; Moazzami AA
Eur J Nutr; 2019 Dec; 58(8):3109-3119. PubMed ID: 30392136
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome.
Le Gall G; Noor SO; Ridgway K; Scovell L; Jamieson C; Johnson IT; Colquhoun IJ; Kemsley EK; Narbad A
J Proteome Res; 2011 Sep; 10(9):4208-18. PubMed ID: 21761941
[TBL] [Abstract][Full Text] [Related]
5. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J
Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586
[TBL] [Abstract][Full Text] [Related]
6. Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome.
Mujagic Z; Kasapi M; Jonkers DM; Garcia-Perez I; Vork L; Weerts ZZRM; Serrano-Contreras JI; Zhernakova A; Kurilshikov A; Scotcher J; Holmes E; Wijmenga C; Keszthelyi D; Nicholson JK; Posma JM; Masclee AA
Gut Microbes; 2022; 14(1):2063016. PubMed ID: 35446234
[TBL] [Abstract][Full Text] [Related]
7. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Wei W; Wang HF; Zhang Y; Zhang YL; Niu BY; Yao SK
World J Gastroenterol; 2020 Dec; 26(45):7153-7172. PubMed ID: 33362374
[TBL] [Abstract][Full Text] [Related]
8. Identification of Gut Microbiota and Metabolites Signature in Patients With Irritable Bowel Syndrome.
Zhu S; Liu S; Li H; Zhang Z; Zhang Q; Chen L; Zhao Y; Chen Y; Gu J; Min L; Zhang S
Front Cell Infect Microbiol; 2019; 9():346. PubMed ID: 31681624
[No Abstract] [Full Text] [Related]
9. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Maharshak N; Ringel Y; Katibian D; Lundqvist A; Sartor RB; Carroll IM; Ringel-Kulka T
Dig Dis Sci; 2018 Jul; 63(7):1890-1899. PubMed ID: 29777439
[TBL] [Abstract][Full Text] [Related]
10. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
Hong G; Li Y; Yang M; Li G; Qian W; Xiong H; Bai T; Song J; Zhang L; Hou X
Neurogastroenterol Motil; 2020 Nov; 32(11):e13891. PubMed ID: 32449259
[TBL] [Abstract][Full Text] [Related]
11. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
12. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.
Tanaka Y; Yamashita R; Kawashima J; Mori H; Kurokawa K; Fukuda S; Gotoh Y; Nakamura K; Hayashi T; Kasahara Y; Sato Y; Fukudo S
J Gastroenterol; 2022 Oct; 57(10):748-760. PubMed ID: 35908139
[TBL] [Abstract][Full Text] [Related]
13. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome.
Tian Z; Zhuang X; Luo M; Yin W; Xiong L
BMC Gastroenterol; 2020 Mar; 20(1):73. PubMed ID: 32178625
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics Analysis of Gut Microbiota and Metabolites in Rats With Irritable Bowel Syndrome.
Liu S; Si C; Yu Y; Zhao G; Chen L; Zhao Y; Zhang Z; Li H; Chen Y; Min L; Zhang S; Zhu S
Front Cell Infect Microbiol; 2019; 9():178. PubMed ID: 31192167
[TBL] [Abstract][Full Text] [Related]
15. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption.
Jeffery IB; Das A; O'Herlihy E; Coughlan S; Cisek K; Moore M; Bradley F; Carty T; Pradhan M; Dwibedi C; Shanahan F; O'Toole PW
Gastroenterology; 2020 Mar; 158(4):1016-1028.e8. PubMed ID: 31843589
[TBL] [Abstract][Full Text] [Related]
16. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
[TBL] [Abstract][Full Text] [Related]
17. The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome.
Shankar V; Homer D; Rigsbee L; Khamis HJ; Michail S; Raymer M; Reo NV; Paliy O
ISME J; 2015 Aug; 9(8):1899-903. PubMed ID: 25635640
[TBL] [Abstract][Full Text] [Related]
18. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.
Sun Q; Jia Q; Song L; Duan L
Medicine (Baltimore); 2019 Feb; 98(7):e14513. PubMed ID: 30762787
[TBL] [Abstract][Full Text] [Related]
19. Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome.
Yu LM; Zhao KJ; Wang SS; Wang X; Lu B
World J Gastroenterol; 2018 Feb; 24(8):894-904. PubMed ID: 29491683
[TBL] [Abstract][Full Text] [Related]
20. An investigation of fecal volatile organic metabolites in irritable bowel syndrome.
Ahmed I; Greenwood R; Costello Bde L; Ratcliffe NM; Probert CS
PLoS One; 2013; 8(3):e58204. PubMed ID: 23516449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
